


PRODUCT INFORMATION



Dovitinib

Item No. 15220

CAS Registry No.: 405169-16-6
Formal Name: 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone
Synonyms: CHIR258, TKI-258
MF: C₂₁H₂₁FN₆O
FW: 392.4
Purity: ≥98%
UV/Vis.: λ_{max}: 232, 290, 368 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Dovitinib is supplied as a crystalline solid. A stock solution may be made by dissolving the dovitinib in the solvent of choice, which should be purged with an inert gas. Dovitinib is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of dovitinib in these solvents is approximately 5 mg/ml.

Description

Dovitinib is a multi-kinase inhibitor.¹ It inhibits the receptor tyrosine kinases FLT3, CSF1R, and c-Kit (IC₅₀s = 1, 36, and 2 nM, respectively), as well as FGFR1, FGFR3, VEGFR1-3, PDGFRα, and PDGFRβ (IC₅₀s = 8, 9, 10, 13, 8, 27, and 210 nM, respectively). Dovitinib inhibits proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC₅₀s = 90-550 and >2,500 nM, respectively). It decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells when used at a concentration of 500 nM. Dovitinib (3-300 mg/kg for eight days) inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice.² It reduces tumor growth in KM12L4A colon, DU145 prostate, and MV4-11 acute myelogenous leukemia mouse xenograft models with ED₅₀ values of 17, 23, and 3 mg/kg per day, respectively.

References

1. Trudel, S., Li, Z.H., Wei, E., *et al.* CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. *Blood* **105**(7), 2941-2948 (2005).
2. Renhowe, P.A., Pecchi, S., Shafer, C.M., *et al.* Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors. *J. Med. Chem.* **52**(2), 278-292 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM